Continuing our series debunking common misconceptions in Regulatory Affairs.
The myth: Many MedTech manufacturers treat gap analyses as administrative exercises. Documents created to satisfy auditors or tick a compliance box. They’re often seen as retrospective paperwork rather than proactive tools.
The reality: A well-executed gap analysis is a strategic planning instrument, not documentation for its own sake. When regulatory requirements change, as with the FDA Pre-RFD guidance, the gap between your current processes and the new requirements represents real operational risk.
Consider this: The FDA’s updated guidance now requires three separate documents for OCP responses. If your current SOP only mentions “respond to FDA requests,” you have a gap. That gap translates to potential submission delays, requests for additional information, or worse, rejection.
The practical difference:
- Reactive approach: Wait until a submission is questioned, then scramble to understand what changed
- Proactive approach: Identify gaps before they affect your submissions, update SOPs systematically, and train staff accordingly
Gap analyses don’t just document what’s different. They tell you what action to take and why it matters. That’s the difference between compliance paperwork and Regulatory Intelligence.
Stay tuned for more myths to be busted next month or reach out to us via info@eumediq.eu.